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Abstract
Background: The current influenza vaccines are effective against seasonal influenza, but cannot be manufactured
in a timely manner for a sudden pandemic or to be cost-effective to immunize huge flocks of birds. We propose a
novel influenza vaccine composing a bacterial carrier and a plasmid cargo. In the immunized subjects, the bacterial
carrier invades and releases its cargo into host cells where the plasmid expresses viral RNAs and proteins for
reconstitution of attenuated influenza virus. Here we aimed to construct a mouse PolI-driven plasmid for efficient
production of influenza virus.
Results: A plasmid was constructed to express all influenza viral RNAs and proteins. This all-in-one plasmid resulted in
105–106 50 % tissue culture infective dose (TCID50)/mL of influenza A virus in baby hamster kidney (BHK-21) cells on the
third day post-transfection, and also reconstituted influenza virus in Madin–Darby canine kidney (MDCK) and Chinese
hamster ovary (CHO) cells. A 6-unit plasmid was constructed by deleting the HA and NA cassettes from the all-in-one
plasmid. Cotransfection of BHK-21 cells with the 6-unit plasmid and the two other plasmids encoding the HA or NA
genes resulted in influenza virus titers similar to those produced by the 1-plasmid method.
Conclusions: An all-in-one plasmid and a 3-plasmid murine PolI-driven reverse genetics systems were developed, and
efficiently reconstituted influenza virus in BHK-21 cells. The all-in-one plasmid may serve as a tool to determine
the factors inhibiting virus generation from a large size plasmid. In addition, we recommend a simple and robust
“1 + 2” approach to generate influenza vaccine seed virus.
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Background
Influenza viruses belong to the Orthomyxoviridae family,
which are characterized by segmented negative sense
RNA genomes. The viral RNAs (vRNAs) are bound by nu-
cleoprotein (NP) and three viral polymerase subunits
(PB1, PB2, and PA) to form a ribonucleoprotein (RNP)
complex, the minimal replication unit [1–3]. Influenza
vRNAs have conserved 5′ and 3′ terminals that contain
all the signals necessary for transcription, replication, and
packaging [4, 5]. vRNAs with precise 5′ and 3′ ends are
generally obtained using the RNA polymerase I (PolI) pro-
moter [6, 7]. Viral polymerase subunits and nucleoprotein
are synthesized under the regulation of the RNA polymer-
ase II (PolII) promoter [8]. To generate influenza virus,
pure plasmid-based reverse genetics systems are
developed using 12–17 plasmids [9, 10]. Invention of the
PolI-PolII bidirectional transcription vector results in a
more robust 8-plasmid system [11, 12]. Due to the fact
that PolI promoters are species-specific [13], different re-
verse genetics systems are developed for primate, avian,
and canine cells [9, 14–16]. A universal T7 promoter-
based system has been built, but shows less efficiency than
the PolI-based bidirectional transcription system [17].
Through tandem ligation of multiple viral gene cassettes,
influenza virus is reconstituted using a 3-plasmid system
[18], and a single DNA construct [19, 20].
An important application of reverse genetics is the
generation of influenza vaccine seed viruses [21–23].
Usually, seasonal influenza vaccine is composed of two
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influenza A viruses and one influenza B virus. Using
the reverse genetics method, each seed virus is generated
with HA and NA from a circulating strain, and the
remaining six segments from a high-yield strain or an at-
tenuated strain [24–26]. Nonetheless, manufacture of the
vaccines still heavily relies on embryonated hens’ eggs or
cell culture to grow the viruses [27], two time-consuming
processes which are unlikely to provide adequate vaccines
for a sudden influenza pandemic. The majority of vaccines
are administered through intramuscular injection or by
individually nasal spray, two labor-intensive ways which
further increase the cost of current vaccines in vaccinating
huge flocks of birds. To develop a quick-manufacturable
and low-cost influenza vaccine, we proposed that an
influenza viral genome-encoding plasmid could be
delivered in vivo by a bacterial carrier, resulting in
production of attenuated influenza viruses to induce pro-
tective immunity against influenza [19]. In a feasibility
study, we constructed a chicken PolI-driven plasmid ex-
pressing all vRNAs, NP and polymerase from a influenza
A virus (A/WSN/33) [19]. Generation of influenza virus
was found in cultured avian cells infected by auxotrophic
Salmonella strains carrying the plasmid or its derivatives,
but not in chickens inoculated with the recombinant
Salmonella [28]. The study proved that a single plasmid
could be constructed to reconstitute influenza virus and
stably maintained in engineered Salmonella strains. The
engineered Salmonella could deliver the plasmid into host
cells resulting in generation of live influenza virus. None-
theless, to make the hypothesized influenza vaccine, the
one-plasmid reverse genetics system still needs to be im-
proved in virus generation efficiency, and the Salmonella
carrier has to be engineered to deliver plasmid efficiently,
especially in vivo.
The mouse represents an easily handling animal and is
widely used in studies of influenza virus, Salmonella
and vaccine development. A large number of well-
characterized rodent cell lines provide another advantage
for in vitro study. Therefore, a mouse PolI-driven one-
plasmid system is very useful to determine the factors
limiting virus generation and Salmonella-mediated plas-
mid delivery. Some rodent cell lines, such as Chinese
hamster ovary (CHO) cells and baby hamster kidney
(BHK-21) cells, are widely used for research and vaccine
development [29–31]. BHK-21 cells synthesize α-2, 3 and
α-2, 6 sialic acid (SA) linked receptors [32], and support
the growth of influenza A and B viruses [32, 33]. BHK-21
cells are also highly transfectable, even with 30-kb plas-
mids [34], and therefore are an appropriate cell substrate
for rodent PolI-based reverse genetics systems.
In this study, we constructed a mouse PolI-driven
all-in-one plasmid to reconstitute influenza virus. A “1 + 2”
plasmid strategy was also tested to simplify the yearly
generation of influenza vaccine seeds.
Results
Plasmid construction
Using the truncated mouse PolI promoter (MPI, 250 bp),
plasmid pYA4924 was constructed to transcribe negative
sense EGFP RNA flanked by the 5′ and 3′ non-translating
regions of influenza virus M segment (vRNA-like). EGFP
expression was observed in BHK-21 cells only when
pYA4924 has been cotransfected with plasmids encoding
influenza polymerase and NP (Data not shown), suggest-
ing that the cloned MPI is functional in hamster cells. By
combining MPI with the SV40 polyadenylation sequence
(SV40 pA, 131 bp), truncated mouse PolI terminator
(MTI, 41 bp), and functional truncated CMV promoter
(188 bp), a bidirectional CMV/MPI-driven transcription
vector, pYA4963, was constructed. Two BsmBI sites were
designed between MPI and MTI to allow precise insertion
of influenza cDNA. A BamHI site was designed between
the two BsmBI sites. By inserting a prokaryotic GFP-
expression cassette at the BamHI site, an easy-to-use
bidirectional vector pYA4964 was constructed (Fig. 1).
Substitution of the GFP cassette with influenza cDNA re-
sulted in loss of green fluorescence in bacterial host cells.
The GFP-based selection method facilitated construction
of the mouse PolI-driven 8-plasmid system that included
plasmids pYA4965 (PB1), pYA4966 (PB2), pYA4967 (PA),
pYA4968 (NP), pYA4969 (HA), pYA4970 (NA), pYA4971
(M), and pYA4972 (NS) (Table 1).
To combine all CMV/MPI-driven influenza gene cas-
settes on one plasmid, four influenza cassettes were first
cloned into a linearized vector which has single 3′-T over-
hangs on both ends (T-vector) (Fig. 2). Unique restriction
enzyme cleavage sites were designed at each end of the
cassette to allow insertion of the other cassette. A prokary-
otic GFP cassette was first inserted between two adjacent
enzyme sites, followed by selection of green colonies
under excitation with 488 nm light. The GFP cassettes
were then substituted with influenza cassettes by selecting
non-fluorescent colonies. These steps resulted in four 2-
unit plasmids, with each unit representing a bidirectional
influenza cassette. The GFP cassettes were again inserted
into three of the 2-unit plasmids. Each of the two 2-unit
plasmids were combined to obtain two 4-unit plasmids,
pYA4988 and pYA4989. Combination of the 4-unit plas-
mids resulted in the all-in-one plasmid pYA4990 which
was further confirmed by sequencing. The all-in-one plas-
mid was designed to transcribe all eight vRNAs and eight
mRNAs (10 mRNAs after spliced) in rodent cells. The HA
and NA cassettes in pYA4990 were deleted to form a
6-unit plasmid that composes a “1 + 2” plasmid system
with the HA and NA plasmids (pYA4969 and pYA4970).
Plasmid stability in E. coli
The all-in-one plasmid contains repetitive sequences in
the promoter and terminator elements flanking each of
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the viral genes (Fig. 2). Homologous DNA recombin-
ation among these repetitive sequences impairs plasmid
stability. To stably maintain and amplify the plasmid, an
E. coli strain with a recA mutation was used. As shown
in Fig. 3, plasmid pYA4990 was electroporated into E.
coli strain EPI300 (RecA−). A single colony was first
inoculated in 3 ml of growth media, and passaged at
dilution ratio of 1:1000. DNA recombination was moni-
tored by restriction enzyme digestion of plasmid DNA
isolated from different passages. At the fourth passage,
there was apparent change in the restriction map of
pYA4990, indicating significantly impaired plasmid
structure. Qualitative evaluation of the DNA bands on
agarose gels suggested that the plasmid structure was
stable for the first 3 passages in E. coli strain EPI300.
From three independent assays, we observed consistent
results. We also tested pYA4490 recombination in an-
other E. coli strain Stbl3 (RecA−) and got similar result
(data not shown). In theory, three passages could result
in 3 × 109 ml of bacterial culture for plasmid prepar-
ation. Therefore, DNA recombination does not represent
a big problem with the all-in-one plasmid when an
E. coli strain with a recA mutation is used during cloning
and plasmid amplification processes.
Virus generation
To test virus generation, 4 μg of the all-in-one plasmid
pYA4990 was used to transfect BHK-21, CHO, or
MDCK cells. For BHK-21 cells, the virus titers ranged
from 1 to 3 × 105 median tissue culture infective dose
(TCID50) per mL on the third day post-transfection (Ex-
periments 1–3; Table 2). When less confluent BHK-21
cells were used in transfection, the virus titers went up
to 3–6 × 106 TCID50/mL (Experiments 4–6). In contrast,
the CHO cells showed very poor virus generation (0–10
TCID50/mL) on the third day post-transfection. The
MDCK cells showed inconsistent virus generation
ranged from 0 to 1 × 106 TCID50/mL on the third day
post-transfection. In Experiments 4–6, the virus titers
went up to 1–3 × 107 TCID50/mL on the fifth day (not
shown in Table 2). As control, 4 μg of the 6-unit plasmid
pYA5000 was transfected into each type of cells. No
virus generation was observed. To test the “1 + 2”
plasmid system, 4 μg of the 6-unit plasmid pYA5000 was
cotransfected into either BHK-21 or MDCK cells with
2 μg of the HA plasmid pYA4969 and 2 μg of the NA
plasmid pYA4970. Although, no virus generation was
observed in MDCK cells, the “1 + 2” approach resulted
in similar titers of influenza virus in BHK-21 cells as the
all-in-one plasmid pYA4990 in the parallel experiments
(Table 2).
We found that the transfected BHK-21 cells detached
but remained viable in media containing 2 μg/ml
TPCK-trypsin, the virus yield was around 105 TCID50/
ml (data not shown). TPCK-trypsin at a concentration
of 0.2 μg/ml did not apparently affect cell attachment
but provided as consistent virus yields as the trypsin-
free condition. The generated viruses were confirmed
to be influenza A virus by western blot analysis with
antibodies specific to the NP and M2 proteins (data not
shown). We also extracted vRNA from influenza virus
generated in BHK-21 cells. The HA and NA segments
were reverse transcribed and amplified by PCR. Se-
quencing results showed that influenza virus from three
Fig. 1 Illustration of the bidirectional vector. A cytomegalovirus (CMV) promoter and Simian virus 40 (SV40) polyadenylation signal (pA) direct the
synthesis of mRNA. The mouse RNA PolI promoter (MPI) and terminator (MTI) compose the vRNA transcription unit. Between the two BsmBI sites,
there is a prokaryotic green fluorescent protein (GFP) gene cassette. The MPI and MTI sequences adjacent to GFP cassette are shown in blue or purple.
Substitution of the GFP cassette with the influenza virus gene resulted in the loss of green fluorescent protein expression in the bacterial host
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experiments had identical HA and NA coding sequences
as encoded by the all-in-one plasmid.
Transfection efficiency
The BHK-21, CHO, and MDCK cells in 80–90 % conflu-
ence were transfected with a 6.1-kb plasmid pYA4731
(CMV-mCherry) or a 25.3-kb plasmid pYA4732 (CMV-
mCherry) [19]. Both plasmids resulted in similar levels of
mCherry expression in BHK-21 and in MDCK cells
(Fig. 4). The CHO cells showed preferential uptake of the
smaller plasmid. The three types of cells were cotrans-
fected with pYA4924 and pYA4732 which encodes influ-
enza viral polymerase and NP. The BHK-21 and CHO
cells showed efficient EGFP expression, indicating that the
vRNA-like molecules were converted into mRNA. In
contrast, only numerous MDCK cells expressed EGFP,
which suggests that the mouse PolI promoter is poorly
active in canine cells.
Discussion
To combat influenza virus infections, the inactivated
and attenuated vaccines remain the most effective tools
[35]. The time-consuming manufacture process and
labor-intensive immunization methods of current vac-
cines render them suboptimal for an influenza pandemic
or huge flocks of birds. Recently, we proposed a novel
influenza vaccine which composes a bacterial carrier
harboring an influenza plasmid [19, 28]. The vaccine can
be quickly propagated in simple media in large scale,
and potentially be orally administered. In vivo delivery of
the influenza plasmid results in generation of attenuated
influenza virus which in turn induces protective immun-
ity. The feasibility study showed that such a form of
recombinant bacteria could be constructed and used to
mediate generation of influenza virus [28]. As expected,
there are limiting factors still needing to be overcome,
such as inefficient virus generation from the influenza
plasmid. In this study we aimed to construct a mouse
PolI-driven plasmid for reconstitution of influenza virus,
so that we can determine the factors limiting virus
generation in the future using well-characterized rodent
cell lines.
The whole set of vRNA, neucleoprotein and three
polymerase subunits are the minimal components re-
quired to initiate influenza virus replication and pack-
aging [3, 9]. The virus production efficiency may be
improved by coexpression of proteins from M, MS, HA
and NA segments [9]. Synthesis of these proteins
requires four more copies of PolII promoter and ter-
minator sequence. This increase in plasmid size, how-
ever, has a negative effect on the nuclear import of
plasmid DNA and virus production [19, 36]. To solve
this problem, we used a short PolII terminator (SV40
pA) and a truncated less-active CMV promoter (data
not shown). With these changes, we made the 21-kb
all-in-one plasmid, which is 2.6 kb less in size than the
8-cassette influenza plasmid described previously [19].
We did not consider to use the T7 promoter-based
system, as it is less efficient than the PolI-PolII bidirec-
tional transcription system [17], and requires coexpres-
sion of T7 RNA polymerase.
Transfection of BHK-21 cells with plasmid pYA4990
resulted in high titers of influenza virus, most likely
because the cells synthesize α-2, 6 SA-linked influenza
receptor [32] and can be efficiently transfected by large
size plasmids [34]. The CHO cells, another hamster cell
line, only yielded merely detectable influenza virus.
One reason is that CHO cells do not have α-2, 6 SA-
linked receptor to support influenza virus propagation
[37, 38]. These two hamster cell lines may help deter-
mine the mechanism limiting nuclear import of the
large size plasmid and the factors inhibiting virus
generation. A plasmid enable to overcome the barriers
Table 1 Plasmids used in the study
Plasmid type Plasmid (related properties) ori and marker
Vector plasmid pcDNA3.1(−) (CMV, SV40 pA) pUC ori, ApR
T-vector precursor pYA4518 (AhdI-GFP cassette-AhdI) p15A ori, CmR
Reporter plasmid pYA4392 (CPI-EGFP), pYA4924
(MPI-EGFP)
pYA4332 (GFP cassette) pUCori, ApR
pYA4731 (CMV-mCherry)
pYA4732 (CMV-mCherry, PB2,
PB1, PA, NP, HA, NA, M, NS)
p15A ori, CmR;
MPI-based
bidirectional vector
pYA4963 (CMV-MPI), pYA4964
(CMV-GFP cassette-MPI)
pUCori, ApR
CPI-based 8-plasmid
system
pYA4383 (PB2), pYA4384 (PB1),
pYA4385 (PA), pYA4386 (NP),
pYA4388 (HA), pYA4389 (NA),
pYA4390 (M), pYA4391 (NS)
MPI-based 8-plasmid
system
pYA4965 (PB1), pYA4966 (PB2),
pYA4967 (PA), pYA4968 (NP),
pYA4969 (HA), pYA4970 (NA),
pYA4971 (M), pYA4972 (NS)
1-unit plasmid pYA4973 (PB1), pYA4974 (NP),
pYA4975 (NA), pYA4976 (NS);
pYA4977 (PB1,GFP), pYA4978
(NP, GFP), pYA4979 (NA,GFP),
pYA4980 (NS,GFP)
p15A ori, CmR
2-unit plasmid pYA4981 (PB1,PB2), pYA4982
(NP,PA), pYA4983 (NA,HA),
pYA4984 (NS,M), pYA4985
(PB1,PB2,GFP), pYA4986
(NP,PA,GFP), pYA4987
(NS,M,GFP)
4-unit plasmid pYA4988 (NP, PA, PB1, PB2,GFP),
pYA4989 (NS, M, NA, HA)
8-unit plasmid pYA4990 (NP, PA, PB1, PB2, NS,
M, NA, HA)
6-unit plasmid pYA5000 (NP, PA, PB1, PB2, NS, M)
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should reconstitute influenza virus efficiently in wide
range of cells such as intestinal epithelial cells, there-
fore can be used to develop the proposed influenza
vaccine.
Each seed virus of influenza vaccines is generated
yearly with HA and NA genes from a circulating influ-
enza virus, and the remaining backbone segments (PB1,
PB2, PA, NP, M and NS) from a high-yield or cold-
Fig. 2 Construction of the all-in-one plasmid. a Using primers engineered with unique restriction enzyme cleavage sites, the NP, PB1, NS, and NA
cassettes from pYA4968 (NP), pYA4965 (PB1), pYA4972 (NS), and pYA4970 (NA) were amplified and cloned into the pYA4518-derived T-vector to
obtain four 1-unit plasmids pYA4974 (NP), pYA4973 (PB1), pYA4976(NS), and pYA4975 (NA). b The GFP cassettes were amplified from pYA4964
and inserted into the four 1-unit plasmids between SmaI, and the adjacent enzyme site downstream each influenza gene cassette. The resulting
plasmids were pYA4978 (NP, GFP), pYA4977 (PB1, GFP), pYA4980 (NS, GFP), and pYA4979 (NA, GFP). c The PA, PB2, M, and HA cassettes were amplified
from pYA4967 (PA), pYA4966 (PB2), pYA4971 (M), and pYA4969 (HA) to replace the GFP cassettes in the 1-unit plasmids from step b. The resulting
2-unit plasmids were pYA4982 (NP, PA), pYA4981 (PB1, PB2), pYA4984 (NS, M), and pYA4983 (NA, HA). d The GFP cassettes were amplified from
pYA4964 and inserted into three of the 2-unit plasmids. The resulting plasmids were pYA4986 (NP, PA, GFP), pYA4985 (PB1, PB2, GFP), and
pYA4987 (NS, M, GFP). e The AsiSI-XmaI fragments from plasmids pYA4986 (NP, PA, GFP) and pYA4985 (PB1, PB2, GFP) were combined to obtain
a 4-unit plasmid pYA4988 (NP, PA, PB1, PB2, GFP). The AsiSI-XmaI fragments from plasmids pYA4987 (NS, M, GFP) and pYA4983 (NA, HA) were
combined to obtain another 4-unit plasmid pYA4989 (NS, M, NA, HA). f The two 4-unit plasmids were digested with BssHII and XmaI. Combination
of the fragments containing influenza cassettes resulted in the all-in-one plasmid pYA4990. The PA, PB2, M, HA, and GFP cassettes had triple C (CCC) at
their 3′-end for connecting to the SmaI-generated blunt end (as shown by primer sequence in Table 3). The SmaI and XmaI endonucleases
were isoschizomers. For clarity, each element is labeled at only one location in plasmid pYA4990
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adapted virus [26, 39, 40]. Since the backbone encoding
segments remain the same every year, they can be used
to make a 6-cassete plasmid. The 6-cassete plasmid
forms a 3-plasmid reverse genetics system with the two
plasmids encoding HA and NA genes. This “1 + 2” ap-
proach was proven successful in the BHK-21 cells
(Table 2). We then tested virus generation in CHO cells
which have been used to produce human vaccines and
other therapeutics for many years [31]. The all-in-one
plasmid could reconstitute low titers of influenza virus
in CHO cells, but the “1 + 2” strategy was not successful.
This may be overcome by using CHO cells expressing
influenza receptor [41–43], or coculture of CHO and
MDCK cells. On the other hand, it also suggests that a
more comprehensive system yields higher titers of virus
[18]. The 3-plasmid system should reconstituteseed virus
more efficiently than an 8-plasmid system in CEF, Vero
cells and MDCK cells [44]. In other circumstance, if one
needs to generate a large number of influenza viruses
merely different in one gene, such as NP, a 7-cassette
plasmid may be constructed to compose a 2-plasmid
system with the NP plasmid. If just numerous influenza
viruses need to be generated, it is not worth the time to
construct a complicated plasmid, and an 8-plasmid sys-
tem should be used.
Given the well-known fact that the PolI promoter is
species-specific, the human PolI promoter is, however,
highly active in MDCK cells [45]. The mouse PolI pro-
moter was found to be active in hamster cell lines, but
showed very poor or no activity in MDCK cells. The
results suggest that it is an inefficient process to produce
the first viral particle in MDCK cells transfected by the
all-in-one plasmid as a result of poor vRNA transcrip-
tion. However, once a live influenza viral particle is
generated, it can replicate rapidly in MDCK cells. Like
the finding with CHO cells, the 3-plasmid system did
not reconstitute influenza virus in MDCK cells. This is
because cotransfection of three plasmids into MDCK
cells is less efficient than a plasmid, and leads to even
less vRNA production in canine cells.
Construction of a plasmid containing all influenza
genes driven by different promoters could be laborious
and time consuming. As shown in Fig. 2, we simplified
and speeded up the process with multiple strategies
including parallel construction of multiple plasmids,
GFP-based selection, use of a low copy plasmid vector
[19], and use of E. coli strains with a recA1 mutation [46,
47]. During gel purification of vector and fragment
DNA, UV transillumination causes cross-linking of
nucleosides and profoundly reduces transformation
frequencies of ligation product, especially for large DNA
constructs [48]. During construction of the 4-unit and
the all-in-one plasmids, the DNA fragments were there-
fore prepared by staining the agarose gel with crystal
violet [49] and detected under white light illumination.
Fig. 3 Homologous recombination of plasmid pYA4990. E. coli recA1
mutant strain EPI300 was transformed with plasmid pYA4990. A
single colony was rotary cultured in LB media containing 25 μg/ml
chloramphenicol at 37 °C for 12 h (passage 0). The culture was
diluted at the ratio of 1:1000, and cultured at same condition for
additional four passages. Plasmid DNA was extracted from each
passage, and digested with EcoRI and KpnI. From an intact plasmid
pYA4990, the size of five theoretical fragments are 8384 bp,
5166 bp, 3747 bp, 1944 bp, and 1798 bp
Table 2 Influenza virus generation in different cell lines (TCID50/mL)
Cell Plasmid Transfection
1 2 3 4 5 6
BHK-21 “1 + 2” plasmidsa 3 × 105 1 × 105 1 × 105 - - -
pYA4990 1 × 105 3 × 105 3 × 105 6 × 106 3 × 106 6 × 106
pYA5000 0 - - - - -
CHO pYA4990 10 0 10 - - -
pYA5000 0 - - - - -
MDCK “1 + 2” plasmids 0 0 0 - - -
pYA4990 3 × 105 3 × 105 0 3 × 103 1 × 106 3 × 103
pYA5000 0 - - - - -
- Not performed
a pYA4969, pYA4970, and pYA5000
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Conclusions
We developed mouse PolI-driven reverse genetics sys-
tems of influenza virus. Both the all-in-one plasmid and
“1 + 2” plasmid system were efficient in generation of in-
fluenza virus in BHK-21 cells, but not in CHO cells used
in the study. The all-in-one plasmid is an ideal tool to
determine the mechanism limiting nuclear import of the
large size plasmid and the factors inhibiting virus gener-
ation using well-characterized rodent cell lines. In
addition, we recommend a more simple and efficient
“1 + 2” plasmid system to generate seed virus of influ-
enza vaccine where one plasmid encodes backbone
segments (PB1, PB2, PA, NP, M, NS) from a high-yield
or cold-adapted strain, and remains the same every year.
The other two plasmids are constructed yearly by
cloning the HA and NA genes from a circulating strain
of influenza virus.
Methods
Bacterial strain and cell lines
The Escherichia coli recA1 mutant strain EPI300 (Epi-
centre) was used for all DNA cloning. Baby hamster kidney
(BHK-21) cells, Chinese hamster ovary (CHO) cells, and
Madin-Darby canine kidney (MDCK) cells were main-
tained in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10 % fetal bovine serum (FBS), 100 U/
mL penicillin, and 100 μg/mL streptomycin.
Plasmid construction
The PfuUltra High-Fidelity DNA polymerase (Stratagene)
was used to amplify the influenza genes and cassettes in
the current study. Agarose gel containing 10 μg/mL of
crystal violet was used to isolate large DNA fragments.
The plasmids and primers used in the study are presented
in Tables 1 and 3.
From plasmid pYA4392 [19], the DNA fragment con-
taining truncated mouse PolI terminator (MTI, 41 bp)
and EGFP gene was amplified with primers P1 and P2.
The 250 bp truncated mouse RNA PolI promoter (MPI)
was amplified from BALB/c mouse genomic DNA with
primers P3 and P4. The two amplified fragments were
fused by PCR using primers P1 and P4. Purified PCR
products were treated with dATP and Taq DNA poly-
merase to add 3′A at each end. Plasmid pYA4924 was
constructed by cloning the treated PCR product into a
lab-made T-vector derived from pYA4518 [50]. Plasmid
pYA4518 had a p15A ori, a chloramphenicol-resistance
marker (CmR), and a prokaryotic green fluorescent
protein (GFP) gene cassette flanked by two AhdI sites.
Removal of the GFP cassette from plasmid pYA4518
through AhdI digestion resulted in a T-vector for
cloning PCR products.
From plasmid pcDNA3.1(−) (Invitrogen), the SV40
polyadenylation sequence (SV40 pA, 131 bp) was ampli-
fied with primers P5 and P6, and the truncated CMV
promoter (188 bp) was amplified with primers P7 and
P8. The MPI was amplified from pYA4924 with primers
P9 and P10. The 41-bp MTI was introduced by primers
P7 and P10. A DNA fragment containing BglII-CMV-
MTI-BsmBI-BamHI-BsmBI-MPI-SV40pA was obtained
by fusing the three PCR products with primers P5 and
P8. The purified PCR product was digested with BglII
and ligated into pcDNA3.1(−) digested with BstZ17I and
BglII to replace the DNA fragment containing the CMV
promoter, the bovine growth hormone (BGH) pA, and
the neo cassette. The resulting bidirectional vector was
designated as pYA4963. To make an easy-to-use vector,
Fig. 4 Analysis of gene expression in BHK-21, CHO, and MDCK cells. The cells were transfected with reporter plasmids carrying a CMV-driven
mCherry cassette. The large pYA4732 plasmid showed significantly lower mCherry expression in CHO cells than the small pYA4731 plasmid. Cells
were also cotransfected with pYA4732 and pYA4924. The EGFP expression indicated that vRNA-like EGFP RNA was generated from pYA4924 and
converted into mRNA for EGFP synthesis in the presence of the influenza NP and polymerase provided by pYA4732. Compared with BHK-21 and
CHO cells, very few MDCK cells expressed EGFP. Expression of EGFP and mCherry were recorded from the same field
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Table 3 Primers used in the study
Target/template Primer Sequence (5′→ 3′)a
MTI-EGFP/pYA4392 P1 ttgtcgcccggagtactggtcg
P2 attggacctggagataggtagtagaaacaaggtag
MPI/mouse genomic DNA P3 ctaccttgtttctactacctatctccaggtccaat
P4 tacgtctgaggccgagggaaagc
SV40 pA/pcDNA3.1(−) P5 tacagacatgataagatacat
P6 cctcggcctcagacgtaaacttgtttattgcagc
CMV/pcDNA3.1(−) P7 caacttcggaggtcgaccagtactccgggcgacaagagctctgcttatatag
P8 ttaagatctgtacatcaatgggcgtgg
MPI/pYA4924 P9 gctgcaataaacaagtttacgtctgaggccgagg
P10 tggtcgacctccgaagttgggggggtgagacggatccgtctctacctatctccaggtcc
GFP cassette/pYA4332 BglII-lpp taaagatctttgttgtgtgaattaat
BglII-5ST1T2 ttaagatcttccattattgaagcatt
PB1/pYA4384 AarI-1 PB1 taacacctgcagtcaggtagtagaaacaaggcatt
AarI-2 PB1 ttacacctgcgactggggagcgaaagcaggcaaac
PB2/pYA4383 AarI-1 PB2 taacacctgcagtcaggtagtagaaacaaggtcgt
AarI-2 PB2 ttacacctgcgactggggagcgaaagcaggtcaat
PA/pYA4385 BsmBI-1PA taacgtctctaggtagtagaaacaaggtact
BsmBI-2PA ttacgtctctggggagcgaaagcaggtactg
NP/pYA4386 BsmBI-1NP taacgtctctaggtagtagaaacaagggtat
BsmBI-2NP ttacgtctctggggagcaaaagcagggtaga
HA/pYA4388 BsmBI-1HA taacgtctctaggtagtagaaacaagggtg
BsmBI-2HA ttacgtctctggggagcaaaagcaggggaa
NA/pYA4389 AarI-1NA taacacctgcagtcaggtagtagaaacaaggagtt
AarI-2NA ttacacctgcgactggggagcgaaagcaggagttt
M/pYA4390 BsmBI-1 M taacgtctctaggtagtagaaacaaggtagt
BsmBI-2 M ttacgtctctggggagcaaaagcaggtagat
NS/pYA4391 BsmBI-1NS taacgtctctaggtagtagaaacaagggtgt
BsmBI-2NS ttacgtctctggggagcaaaagcagggtgac
NP cassette /pYA4968 PmlI-NP cacgtgtacatcaatgggcgtggatagcg
SmaI-NgoMIV-NP cccgggatagccggcagacatgataagatacat
PA cassette/pYA4967 NgoMIV-PA taagccggcgtacatcaatgggcgtggat
GGG-AsiSI-PA gggatagcgatcgcagacatgataagatacat
PB1 cassette/pYA4965 AsiSI-PB1 gcgatcgcgtacatcaatgggcgtggat
SmaI-NotI-PB1 cccgggatagcggccgcagacatgataagatacat
PB2 cassette/pYA4966 NotI-PB2 taagcggccgcgtacatcaatgggcgtggat
GGG-BssHII-PB2 gggatagcgcgcagacatgataagatacat
NS cassette/pYA4972 BssHII-NS gcgcgcgtacatcaatgggcgtggatag
SmaI-KpnI-NS cccgggataggtaccagacatgataagatacat
M cassette/pYA4971 KpnI-M taaggtaccgtacatcaatgggcgtggat
GGG-PacI-M gggatattaattaacagacatgataagatacat
NA cassette/pYA4970 PacI-NA ttaattaagtacatcaatgggcgtggatag
SmaI-SbfI-NA cccgggatacctgcaggcagacatgataagatacat
HA cassette/pYA4969 SbfI-HA taacctgcagggtacatcaatgggcgtggat
GGG-HA gggcagacatgataagatacattgatg
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the prokaryotic expression GFP cassette was amplified
from pYA4332 with primers BglII-lpp and BglII-5ST1T2.
The GFP cassette was digested with BglII and ligated
into the pYA4963 vector that was digested with BamHI
and treated with calf intestinal alkaline phosphatase
(CIAP); the resulting plasmid was pYA4964 (Fig. 1). The
linearized and ready-to-use pYA4964 was prepared by
removing the GFP cassette with BsmBI. From the
chicken PolI promoter based 8-plasmid system pYA4383
(PB2), pYA4384 (PB1), pYA4385 (PA), pYA4386 (NP),
pYA4388 (HA), pYA4389 (NA), pYA4390 (M), and
pYA4391 (NS) [19], the influenza A virus (A/WSN/
33(H1N1)) genes were amplified by PCR and digested
with BsmBI or AarI. Each treated gene was cloned indi-
vidually into the linearized pYA4964. Only colonies that
did not show green fluorescence under excitation of
488 nm were selected and verified by restriction digestion
of the plasmid DNA. The resulting mouse RNA PolI-
driven 8-plasmid system included plasmids pYA4965
(PB1), pYA4966 (PB2), pYA4967 (PA), pYA4968 (NP),
pYA4969 (HA), pYA4970 (NA), pYA4971 (M), and
pYA4972 (NS).
Using primers engineered with unique restriction en-
zyme cleavage sites, the influenza gene cassettes were
amplified from the mouse PolI-driven plasmids. An all-
in-one plasmid pYA4990 was constructed by combining
all of the cassettes (Fig. 2). The pYA4990 was se-
quenced with 54 primers that target influenza genes
(not shown). To construct a 6-unit plasmid without
HA and NA cassettes, the pYA4990 was digested by
PacI and SmaI. The large linearized fragment was
treated with Klenow large fragment to form blunt ends,
and self-ligated. The resulting plasmid was pYA5000,
which served as the control or constituted the “1 + 2”
plasmids system for generating influenza virus with
plasmids pYA4969 (HA) and pYA4970 (NA).
DNA recombination assay
DNA recombination of the all-in-one plasmid in E. coli
was evaluated as described previously [28].
Transfection
BHK-21, CHO, and MDCK cells grown in 6-well plates
were transfected according to the manufacturer’s in-
structions. Briefly, 2 μL of Lipofectamine 2000 (Invitro-
gen) per μg plasmid DNA were individually diluted in
100 μL of Opti-MEM. After 5 min incubation at room
temperature, the diluted transfection reagent was
mixed with the DNA. After 40 min incubation at room
temperature, the transfection mix was added to pre-
washed cells. After 5 h, the transfection medium was
replaced with DMEM supplemented with 10 % FBS. At
24 h post-transfection, images were acquired using a
Zeiss Axio Cam Mrc-5 mounted onto a Zeiss Axioskop
40-fluorescent microscope.
Virus generation
For influenza virus generation, BHK-21, CHO, or MDCK
cells grown in 6-well plates were transfected with plasmid
DNA as described above. After 5 h of incubation, the
transfection medium was replaced with 2.5 mL of Opti-
MEM containing penicillin and streptomycin. At 24 h
post-transfection, the medium was replaced with 3 mL of
Opti-MEM containing 0.2 μg/mL TPCK-trypsin, 0.3 %
BSA, penicillin, and streptomycin. At three to six days
post-transfection, cell supernates were titrated on MDCK
cell monolayers to estimate influenza virus titers.
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Table 3 Primers used in the study (Continued)
GFP cassette/pYA4964b GGG-5ST1T2 gggtccattattgaagcatttatcaggg
SbfI-lpp taacctgcaggttgttgtgtgaattaatttgt
KpnI-lpp taaggtaccttgttgtgtgaattaatttgt
NotI-lpp taagcggccgcttgttgtgtgaattaatttgt
NgoMIV-lpp taagccggcttgttgtgtgaattaatttgt
PacI-lpp taattaattaattgttgtgtgaattaatttgt
BssHII-lpp taagcgcgcttgttgtgtgaattaatttgt
AsiSI-lpp taagcgatcgcttgttgtgtgaattaatttgt
aThe restriction enzyme sites or the GGG (corresponding to 3′- triple C of the PA, PB2, M, HA, and GFP cassettes in Fig. 2) were underlined
bPrimer GGG-5ST1T2 was paired with each of the other 7 primers for amplifying GFP cassette from pYA4964
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